Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

p53 and p21 expression in bone marrow clots of megaloblastic anemia patients

Full text
Author(s):
Kwan, Denis Nicolas [1] ; Queiroz Rocha, Julia Thalita [2, 3] ; Niero-Melo, Ligia [4] ; Custodio Domingues, Maria Aparecida [2] ; Oliveira, Cristiano Claudino [5, 6]
Total Authors: 5
Affiliation:
[1] Sao Paulo State Univ FMB UNESP, Botucatu Med Sch, Botucatu, SP - Brazil
[2] Sao Paulo State Univ FMB UNESP, Botucatu Med Sch, Dept Pathol, Botucatu, SP - Brazil
[3] Sao Paulo State Univ FMB UNESP, Botucatu Med Sch, Salomao & Zoppi DASA, Botucatu, SP - Brazil
[4] Sao Paulo State Univ FMB UNESP, Botucatu Med Sch, Dept Clin Med, Botucatu, SP - Brazil
[5] Sao Paulo State Univ FMB UNESP, Botucatu Med Sch, Dept Pathol, 266 Bairro Jardim Oriental, BR-04321120 Sao Paulo, SP - Brazil
[6] Hosp Sao Luiz D, Dept Anat Pathol, 266 Bairro Jardim Oriental, BR-04321120 Sao Paulo, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Source: INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY; v. 13, n. 7, p. 1829-1833, 2020.
Web of Science Citations: 0
Abstract

` The pathogenesis of megaloblastic hemopathies (MH) is centered on the deficiency of vitamin B12 and folic acid with interruption of erythrocyte maturation. This study researched the participation of p53 and p21 in the pathophysiology of the disease. A retrospective study enrolled 95 patients with histopathologic diagnosis by biopsy or bone marrow clot (BMB/BMC), with clinical review and immunohistochemical study in tissue microarray (TMA) for p53 and p21, detailing their marking location. All patients had BMC and only 11 had BMB. The CMO was a differential of this study and it allowed an expanded sample. In the TMA, 63.7% (58/91) of the samples were immunopositive for p53; and 35.2% (31/88) were immunopositive for p21. Nuclear staining, divergent from the literature, was observed in 17.3% (10/58) among those p53+ and in 38.7% (12/31) among those p21+. The pattern of immunostaining showed non-significant differences (P=0.474) regarding morphologic and clinical aspects. The positivity for both may indicate an effective balance between apoptosis and anti-apoptotic action. Excessive inhibition of apoptosis would contribute to high global cellularity, but without functional maturation effectiveness. In conclusion, there is p21 and/or p53 immunoexpression in most cases of this study and there is no clear association between immunoexpression pattern and patient outcome. Unlike the literature, we also found a percentage of nuclear immunostaining, but the finding was not statistically significant. Combination of p21 and p53 results created different possibilities of pathologic interpretation for MH, reinforcing the importance of studies similar to this one. (AU)

FAPESP's process: 16/19725-3 - P53 and p21 expression in bone marrow clots of patients with megaloblastic anemia
Grantee:Denis Nicolas Kwan
Support Opportunities: Scholarships in Brazil - Scientific Initiation